Defining and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomas
定义和利用非霍奇金淋巴瘤中 EBV 感染细胞的异质性
基本信息
- 批准号:10706553
- 负责人:
- 金额:$ 55.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-19 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:AdultAfrican Burkitt&aposs lymphomaAgeAnimal ModelB lymphocyte immortalizationB-Cell LymphomasB-Cell NonHodgkins LymphomaB-LymphocytesBehaviorBiological MarkersCell SeparationCell modelCellsClinical TrialsCoupledCytotoxic T-LymphocytesDNA DamageDataDevelopmentEpstein Barr Virus B cell lymphomaEpstein-Barr Virus InfectionsEpstein-Barr Virus latencyExhibitsFailureFrequenciesGanciclovirGene ExpressionGeneticGoalsGrowthHIV InfectionsHerpesviridaeHeterogeneityHistone DeacetylaseHistone Deacetylase InhibitorHumanHuman Herpesvirus 4ImmuneImmunosuppressionIn VitroIndividualInfectionLatent virus infection phaseLymphomaLymphoma cellLymphomagenesisLyticLytic VirusMediatingMinorModelingMolecularMonitorNon-Hodgkin&aposs LymphomaOncogenicOncogenic VirusesOrgan TransplantationOutcomePathogenesisPhenotypePhosphotransferasesPlasmablastPopulationPredispositionProliferatingProtein KinaseRegulationRepressionResearchRestRoleT cell responseTestingTherapeuticTherapeutic InterventionTumor TissueValganciclovirViralViral ProteinsVirusWorkXenograft Modelcell killingepstein barr virus mediated immortalizationexperimental studygene productin vivoinfected B cellinnate immune sensinglarge cell Diffuse non-Hodgkin&aposs lymphomalatent infectionlymphoblastoid cell linemouse modelneoplastic cellnovel therapeuticsprogramsresponsesensorsingle-cell RNA sequencingsuccesstransforming virustumortumor heterogeneitytumor progressiontumorigenesisvirtual
项目摘要
Epstein-Barr virus (EBV) was the first human tumor virus discovered over 50 years ago in the context of
endemic African Burkitt lymphoma. However, we now know it is also a common herpesvirus that persists as a
lifelong latent infection in virtually all adults worldwide. Early work in the field led to a model for EBV infection
promoting B-cell lymphomas as evidenced by the growth transformation, or immortalization, of primary resting
human B cells into lymphoblastoid cell lines (LCLs). In vivo, EBV latent infection is met with a robust cytotoxic
T-cell response keeping most infected individuals protected from the oncogenic potential of the virus. As such,
EBV-associated B-cell lymphomas occur at significantly higher rates in the setting of immune suppression.
Studies of viral and cellular gene expression in EBV-infected cells in vitro and in vivo have led to a model of
lymphomagenesis characterized by the full expression of EBV latency gene products. However, the phenotypes
in bulk culture and tumor tissue lack the nuanced detail of cellular heterogeneity and the consequences of minor
frequency phenotypes on cancer progression. Our recent single cell RNAseq experiments have characterized
gene expression within individual EBV-infected B cells leading to an appreciation of cell fate trajectories and
dynamic gene expression behavior of individual cells that we will integrate with human tumor analysis and mouse
models of lymphomagenesis. It is our ultimate goal to define the importance of specific EBV-infected cell
populations on the progression of B-cell non-Hodgkin lymphomas of the immune suppressed. In this proposal,
we aim to define how EBV-infected cell heterogeneity, including innate antiviral restriction and plasmablast
differentiation, impacts lymphomagenesis and can be exploited for therapy. Our central hypothesis is that EBV-
infected B cells toggle between different states that can restrict or promote lymphomagenesis as well as render
cells susceptible to virus-specific therapeutic intervention. We formulated our central hypothesis based on
preliminary data including single-cell RNA sequencing of EBV-infected primary B cells early after infection and
in LCLs as well as characterization of cell fate dynamics regulating plasmablastic differentiation and lytic
reactivation. We also provide evidence supporting a recent clinical trial using the “kick and kill” strategy of
promoting EBV lytic reactivation with histone deacetylase inhibition coupled with ganciclovir to kill lymphoma
cells that activate viral kinases. Thus, the rationale for the proposed research is that understanding EBV
regulation of infected B-cell fates will dissect mechanisms of pathogenesis and reveal new therapeutic avenues
to target EBV-positive B-cell lymphomas. We plan to test our central hypothesis and complete the objectives in
this proposal through the following three specific aims: i) to define the role of innate immune sensors and
effectors in EBV-mediated immortalization and lymphomagenesis, ii) to determine the role of plasmablast
differentiation in suppressing EBV-mediated lymphomagenesis, and iii) to define the mechanism by which HDAC
inhibition promotes susceptibility of EBV+ DLBCL to killing by ganciclovir.
EB病毒(EBV)是50多年前在人类肿瘤背景下发现的第一种人类肿瘤病毒。
地方性非洲伯基特淋巴瘤然而,我们现在知道它也是一种常见的疱疹病毒,
全世界几乎所有成年人的终身潜伏感染。该领域的早期工作导致了EBV感染的模型
促进B细胞淋巴瘤,如通过原发性静息细胞的生长转化或永生化所证明的
人B细胞转化为淋巴母细胞样细胞系(LCL)。在体内,EBV潜伏感染与强的细胞毒性反应有关。
T细胞反应使大多数感染者免受病毒致癌潜力的影响。因此,在本发明的一个方面,
EBV相关B细胞淋巴瘤在免疫抑制的情况下发生率显著较高。
在体外和体内对EBV感染细胞中的病毒和细胞基因表达的研究已经导致了一种模型,
以EBV潜伏基因产物的完全表达为特征的淋巴瘤发生。然而,表型
在大量培养和肿瘤组织中缺乏细胞异质性的细微细节和微小的细胞异质性的后果。
频率表型对癌症进展的影响我们最近的单细胞RNAseq实验表征了
单个EBV感染的B细胞内的基因表达导致细胞命运轨迹的评估,
单个细胞的动态基因表达行为,我们将与人类肿瘤分析和小鼠肿瘤分析相结合。
淋巴瘤模型。我们的最终目标是确定特定EBV感染细胞的重要性,
人群对B细胞非霍奇金淋巴瘤的进展的免疫抑制。在这一提议中,
我们的目标是确定EB病毒感染的细胞异质性,包括先天性抗病毒限制和浆母细胞,
分化,影响淋巴瘤发生,并可用于治疗。我们的核心假设是EB病毒-
受感染的B细胞在不同的状态之间切换,这些状态可以限制或促进淋巴瘤的发生,
对病毒特异性治疗干预敏感的细胞。我们的核心假设是基于
初步数据包括感染后早期EBV感染的原代B细胞的单细胞RNA测序,
在LCL中以及表征调节浆细胞分化和溶解的细胞命运动力学
重新激活我们还提供了证据支持最近的一项临床试验,该试验使用了"踢死"策略,
组蛋白去乙酰化酶抑制剂联合更昔洛韦促进EBV裂解性再活化杀伤淋巴瘤
激活病毒激酶的细胞。因此,拟议研究的基本原理是,
受感染的B细胞命运的调节将剖析发病机制,并揭示新的治疗途径
针对EB病毒阳性B细胞淋巴瘤我们计划测试我们的中心假设,并完成目标,
该建议通过以下三个具体目标:i)定义先天免疫传感器的作用,
EBV介导的永生化和淋巴瘤发生中的效应物,ii)确定浆母细胞的作用
在抑制EBV介导的淋巴瘤发生中的分化,和iii)定义HDAC
抑制增强了EBV + DLBCL对更昔洛韦杀伤的敏感性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Micah A. Luftig其他文献
Comparison of nanopore with illumina whole genome assemblies of the Epstein-Barr virus in Burkitt lymphoma
- DOI:
10.1038/s41598-025-94737-0 - 发表时间:
2025-03-31 - 期刊:
- 影响因子:3.900
- 作者:
Isaac E. Kim;Abebe A. Fola;Enrique Puig;Titus Kipkemboi Maina;Sin Ting Hui;Hongyu Ma;Kaleb Zuckerman;Eddy O. Agwati;Alec Leonetti;Rebecca Crudale;Micah A. Luftig;Ann M. Moormann;Cliff Oduor;Jeffrey A. Bailey - 通讯作者:
Jeffrey A. Bailey
Author Correction: Highly recurrent CBS epimutations in gastric cancer CpG island methylator phenotypes and inflammation
- DOI:
10.1186/s13059-021-02405-z - 发表时间:
2021-06-17 - 期刊:
- 影响因子:9.400
- 作者:
Nisha Padmanabhan;Huang Kie Kyon;Arnoud Boot;Kevin Lim;Supriya Srivastava;Shuwen Chen;Zhiyuan Wu;Hyung-Ok Lee;Vineeth T. Mukundan;Charlene Chan;Yarn Kit Chan;Ong Xuewen;Jason J. Pitt;Zul Fazreen Adam Isa;Manjie Xing;Ming Hui Lee;Angie Lay Keng Tan;Shamaine Ho Wei Ting;Micah A. Luftig;Dennis Kappei;Warren D. Kruger;Jinsong Bian;Ying Swan Ho;Ming Teh;Steve George Rozen;Patrick Tan - 通讯作者:
Patrick Tan
Epstein-Barr virus induces germinal center light zone chromatin architecture and promotes survival through enhancer looping at the emBCL2A1/em locus
爱泼斯坦-巴尔病毒诱导生发中心亮区染色质结构,并通过 emBCL2A1/em 位点的增强子环化促进存活
- DOI:
10.1128/mbio.02444-23 - 发表时间:
2023-12-11 - 期刊:
- 影响因子:4.700
- 作者:
Joanne Dai;Elliott D. SoRelle;Emma Heckenberg;Lingyun Song;Jana M. Cable;Gregory E. Crawford;Micah A. Luftig;Alan N. Engelman - 通讯作者:
Alan N. Engelman
Micah A. Luftig的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Micah A. Luftig', 18)}}的其他基金
Defining and exploiting EBV-infected cell heterogeneity in non-Hodgkin lymphomas
定义和利用非霍奇金淋巴瘤中 EBV 感染细胞的异质性
- 批准号:
10541348 - 财政年份:2022
- 资助金额:
$ 55.59万 - 项目类别:
Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis
剖析 EBV 和恶性疟原虫在地方性伯基特淋巴瘤发病机制中的作用
- 批准号:
10204966 - 财政年份:2019
- 资助金额:
$ 55.59万 - 项目类别:
Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis
剖析 EBV 和恶性疟原虫在地方性伯基特淋巴瘤发病机制中的作用
- 批准号:
10671667 - 财政年份:2019
- 资助金额:
$ 55.59万 - 项目类别:
Dissecting the role of EBV and P. falciparum in endemic Burkitt lymphoma pathogenesis
剖析 EBV 和恶性疟原虫在地方性伯基特淋巴瘤发病机制中的作用
- 批准号:
10459337 - 财政年份:2019
- 资助金额:
$ 55.59万 - 项目类别:
Defining the Mechanisms of Epstein-Barr Virus Persistence and Recurrence
定义 Epstein-Barr 病毒持续存在和复发的机制
- 批准号:
10437789 - 财政年份:2016
- 资助金额:
$ 55.59万 - 项目类别:
Targeting Apoptosis and Immune Control of Epstein-Barr Virus Infected Tonsillar B Cells
针对 Epstein-Barr 病毒感染的扁桃体 B 细胞的凋亡和免疫控制
- 批准号:
9237256 - 财政年份:2016
- 资助金额:
$ 55.59万 - 项目类别:
Defining the Mechanisms of Epstein-Barr Virus Persistence and Recurrence
定义 Epstein-Barr 病毒持续存在和复发的机制
- 批准号:
10599350 - 财政年份:2016
- 资助金额:
$ 55.59万 - 项目类别:
Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation
调节 Epstein-Barr 病毒介导的 B 细胞生长转化的宿主途径
- 批准号:
10663313 - 财政年份:2011
- 资助金额:
$ 55.59万 - 项目类别:
Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation
调节 Epstein-Barr 病毒介导的 B 细胞生长转化的宿主途径
- 批准号:
8187400 - 财政年份:2011
- 资助金额:
$ 55.59万 - 项目类别:
Host pathways regulating Epstein-Barr virus-mediated B cell growth transformation
调节 Epstein-Barr 病毒介导的 B 细胞生长转化的宿主途径
- 批准号:
8843606 - 财政年份:2011
- 资助金额:
$ 55.59万 - 项目类别: